Study of anecatibin fumarate for people with liver problems
Part of Cancer, Lungs & breathing clinical trials.
This study is testing an experimental drug (called Anecatibin Fumarate) in people with mild or moderate liver problems and in people with healthy livers, to see how the drug is processed by the body and if it's safe. It helps doctors learn if the dose needs to be adjusted for people with liver impairment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 65 years old (inclusive)
- Weigh at least 50 kg (men) or 45 kg (women) with a body mass index (BMI) of 18 to 30
- Have either normal liver function or mild to moderate liver impairment (Child-Pugh A or B)
- Have not taken certain prescription medicines, herbal products, or supplements within 2 to 4 weeks before the study
- Have no serious health issues (other than liver disease, if you have it) such as heart, kidney, or lung disease, or a history of cancer
- Agree to use effective birth control during the study and for 6 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a new oral drug (called INCB161734) is processed by the body and how safe it is in people with liver problems. It may help doctors understand the right dose for patients with liver impairment.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This trial tests how the drug capivasertib is processed by the body and how safe it is in people with moderate liver impairment. It aims to find the right dose for patients whose liver function is reduced but stable.
This study checks how a new investigational drug (catequentinib) interacts with two other common medications in healthy volunteers. Participation helps understand safe dosing and potential side effects before larger studies.
This study tests how a new experimental medicine (INCB123667) works and is tolerated in adults with moderate to severe liver problems. Researchers want to understand how the body processes this drug and whether it's safe in people with liver dysfunction.
This study tests an experimental medicine called ABI-6250 in people with mild liver problems compared to healthy people. It aims to see how the drug affects the body and if it is safe.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.